RedHill Biopharma Ltd.
RDHLAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Aug 31, 2021 |
| WBB Securities | downgrade | Strong Buy →Buy | May 28, 2021 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2021 |
| BTIG | maintain | Buy | Sep 11, 2020 |
| H.C. Wainwright | maintain | Buy | Mar 5, 2020 |
| WBB Securities | upgrade | Buy →Strong Buy | Jul 12, 2019 |
| WBB Securities | maintain | Speculative Buy →Buy | Mar 12, 2019 |
| Ladenburg Thalmann | maintain | Buy | Jun 25, 2018 |
| Nomura | maintain | Buy | Jan 26, 2018 |
| Seaport Global | maintain | Buy | Oct 6, 2017 |
| Northland Securities | maintain | Buy | Sep 29, 2015 |
| Roth Capital | maintain | Buy | Jun 16, 2015 |
| H.C. Wainwright | maintain | Buy | Mar 26, 2015 |
Earnings History
Next report: Mar 18, 2027 · EPS est. $-474.29| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 5, 2025 | $-1.00 | $-690.00 | $2.0M | $4.4M |
| Apr 10, 2025 | $-1.00 | $-690.00 | $2.0M | $4.4M |
| Oct 3, 2024 | $-1.00 | $-690.00 | $2.7M | $4.4M |
| Jul 30, 2024 | $-2.00 | $-0.30 | $1.3M | $25.7M |
| Apr 8, 2024 | $-1.00 | — | $1.3M | $25.7M |
| Mar 14, 2024 | $-0.20 | $-0.03 | $567.5K | $25.7M |
| Nov 6, 2023 | $-24.00 | $1.39 | $567.5K | $24.2M |
| Jun 30, 2023 | $4.83 | $1.19 | $1.8M | $2.1M |
News
In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in both long-term intracellular culture and spot and phage assays The two sets of studies, showing confirmed MAP-killing effect and comparability to RHB-104, led by Professor Tim Bull from City St George's University of London, and Prof Irene Grant, Professor of Microbiology and Food …
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation and Earnings This table compares Redhill
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion TEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Novartis and Redhill Biopharma's net
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materiall…
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability -- Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill's transformational commercial…